Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.54 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.53 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694832 | 0.92 | MLYCD (0.72) | MLYCDEGFRERBB2TP53SMN1; SMN2 | |
| SCHEMBL9645497 | 0.87 | GAA (0.58) | MLYCDEGFRERBB2TP53LPAR1 | |
| SCHEMBL1003735 | 0.86 | TP53 (0.68) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL10762716 | 0.85 | RARB (0.57) | EGFRERBB2TP53HPGDALDH1A1 | |
| SCHEMBL10767369 | 0.85 | RARB (0.57) | EGFRERBB2TP53HPGDALDH1A1 | |
| SCHEMBL10761149 | 0.85 | RARB (0.57) | EGFRERBB2TP53HPGDALDH1A1 | |
| SCHEMBL4489409 | 0.84 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL26313600 | 0.84 | MLYCD (0.64) | MLYCDEGFRERBB2TP53RAB9A | |
| SCHEMBL7967022 | 0.84 | MLYCD (0.64) | MLYCDEGFRERBB2TP53RAB9A | |
| SCHEMBL6802252 | 0.83 | HPGD (0.69) | MLYCDTP53RAB9ASMN1; SMN2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | MLYCD 291/4885EGFR 4163/4885ERBB2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.